{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:33:54Z","timestamp":1767893634690,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,18]]},"DOI":"10.7759\/cureus.37757","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T11:33:03Z","timestamp":1681817583000},"source":"Crossref","is-referenced-by-count":1,"title":["Prolonged Survival in a Patient With Extensive-Stage Small Cell Lung Cancer in Spite of Discontinued Immunotherapy With Atezolizumab"],"prefix":"10.7759","author":[{"given":"Kazuhisa","family":"Konishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroomi","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09034-6","article-title":"Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis","volume":"21","author":"Jiang S","year":"2021","unstructured":"Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer. 2021, 21:1308. 10.1186\/s12885-021-09034-6","journal-title":"BMC Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 impower132 trial","volume":"16","author":"Nishio M","year":"2021","unstructured":"Nishio M, Barlesi F, West H, et al.. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 impower132 trial. J Thorac Oncol. 2021, 16:653-64. 10.1016\/j.jtho.2020.11.025","journal-title":"J Thorac Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al.. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017, 377:1919-29. 10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke C","year":"2016","unstructured":"Pfirschke C, Engblom C, Rickelt S, et al.. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016, 44:343-54. 10.1016\/j.immuni.2015.11.024","journal-title":"Immunity"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger S","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, et al.. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018, 36:1675-84. 10.1200\/JCO.2017.77.0412","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23873","article-title":"Multiparameter flow cytometry assay for quantification of immune cell subsets, PD-1 expression levels and PD-1 receptor occupancy by nivolumab and pembrolizumab","volume":"95","author":"Pluim D","year":"2019","unstructured":"Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JH. Multiparameter flow cytometry assay for quantification of immune cell subsets, PD-1 expression levels and PD-1 receptor occupancy by nivolumab and pembrolizumab. Cytometry A. 2019, 95:1053-65. 10.1002\/cyto.a.23873","journal-title":"Cytometry A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824b23cb","article-title":"Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients","volume":"7","author":"Kim GM","year":"2012","unstructured":"Kim GM, Kim YS, Ae Kang Y, et al.. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. J Thorac Oncol. 2012, 7:731-6. 10.1097\/JTO.0b013e31824b23cb","journal-title":"J Thorac Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/srep18999","article-title":"Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients","volume":"6","author":"Horita N","year":"2016","unstructured":"Horita N, Yamamoto M, Sato T, et al.. Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Sci Rep. 2016, 6:18999. 10.1038\/srep18999","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018, 379:2220-9. 10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14712","article-title":"Prognostic factors for survival in extensive-stage small cell lung cancer: an Italian real-world retrospective analysis of 244 patients treated over the last decade","volume":"13","author":"Longo V","year":"2022","unstructured":"Longo V, Pizzutilo P, Catino A, Montrone M, Pesola F, Marerch I, Galetta D. Prognostic factors for survival in extensive-stage small cell lung cancer: an Italian real-world retrospective analysis of 244 patients treated over the last decade. Thorac Cancer. 2022, 13:3486-95. 10.1111\/1759-7714.14712","journal-title":"Thorac Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01044-3","article-title":"Excellent survival of pathological N0 small cell lung cancer patients following surgery","volume":"28","author":"Fu Z","year":"2023","unstructured":"Fu Z, Li D, Deng C, et al.. Excellent survival of pathological N0 small cell lung cancer patients following surgery. Eur J Med Res. 2023, 28:91. 10.1186\/s40001-023-01044-3","journal-title":"Eur J Med Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14604","article-title":"Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer","volume":"13","author":"Li Y","year":"2022","unstructured":"Li Y, Wang Y, Zhou W, et al.. Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer. Thorac Cancer. 2022, 13:2711-22. 10.1111\/1759-7714.14604","journal-title":"Thorac Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.08.015","article-title":"Real-world evidence for immunotherapy in the first line setting in small cell lung cancer","volume":"172","author":"Sagie S","year":"2022","unstructured":"Sagie S, Maixner N, Stemmer A, Lobachov A, Bar J, Urban D. Real-world evidence for immunotherapy in the first line setting in small cell lung cancer. Lung Cancer. 2022, 172:136-41. 10.1016\/j.lungcan.2022.08.015","journal-title":"Lung Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14684","article-title":"Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice","volume":"13","author":"Yang Y","year":"2022","unstructured":"Yang Y, Ai X, Xu H, et al.. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice. Thorac Cancer. 2022, 13:3295-303. 10.1111\/1759-7714.14684","journal-title":"Thorac Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","volume":"39","author":"Datta M","year":"2019","unstructured":"Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019, 39:165-74. 10.1200\/EDBK_237987","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa A","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al.. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018, 3:1-16. 10.1172\/jci.insight.59125","journal-title":"JCI Insight"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103531","article-title":"Pseudoprogression in lung cancer patients treated with immunotherapy","volume":"169","author":"Chen MY","year":"2022","unstructured":"Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol. 2022, 169:103531. 10.1016\/j.critrevonc.2021.103531","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour L","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al.. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18:e143-52. 10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/145692-prolonged-survival-in-a-patient-with-extensive-stage-small-cell-lung-cancer-in-spite-of-discontinued-immunotherapy-with-atezolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:39Z","timestamp":1707508779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/145692-prolonged-survival-in-a-patient-with-extensive-stage-small-cell-lung-cancer-in-spite-of-discontinued-immunotherapy-with-atezolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.37757","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}